3DP 3534

Drug Profile

3DP 3534

Alternative Names: GW 395058; PEG-TPO

Latest Information Update: 02 Nov 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer 3-Dimensional Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 02 Nov 2005 No development reported - Preclinical for Thrombocytopenia in United Kingdom (unspecified route)
  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
  • 06 Mar 2002 3-Dimensional Pharmaceuticals have announced a collaboration agreement with Inhale Therapeutic Systems
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top